Is This U.S. Pot Stock the New Industry Leader?

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) may have been the dominant name in the cannabis industry thus far, but that might not be the case for much longer.

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth has tried to assert itself atop the cannabis industry in North America. It made a lot of aggressive moves to try and give itself and its investors a lot of potential growth to benefit from in the years ahead.

From locking in a big investor like Constellation Brands to getting a deal in place with Acreage Holdings, the company has made numerous moves to help position itself for success.

Access to U.S. market critical for long-term growth

The problem is that even if investors think Canopy Growth is a good investment, it’s inherently limited. Being restricted to the Canadian market and only being able to sell hemp-based products in the U.S. (for now) has put a limit on to just how much growth the company can achieve in the near future.

Even if the U.S. moves to legalize marijuana, that’s likely not going to happen anytime soon. That’s why Canopy Growth was always going to be a long shot to be the biggest cannabis brand, simply because it didn’t have access to the biggest cannabis market.

Multi-state operator Curaleaf Holdings (CNSX:CURA), however, doesn’t have those same obstacles. With the company not being on the TSX and based in the U.S., Curaleaf has a lot more flexibility in what it can do. And while federally there are still significant challenges, growing via acquisition is one way that the company can expand into other parts of the country, which is what it has done.

This week, Curaleaf released its second-quarter results. Its US$48 million in revenue during the quarter was a 231% improvement from the prior year. On a pro-forma basis, including the company’s acquisitions and assuming they had been completed on January 1, that number soars to US$110.9 million, which would dwarf what we’ve seen thus far from Canadian producers.

The company also reached a milestone on its bottom line as well, posting a positive adjusted EBITDA figure of US$3.4 million for the first time in its history. This was an improvement from the prior year when it incurred a loss of US$3.8 million.

Currently, through acquisitions, Curaleaf now has access to 19 states. With some big acquisitions under its belt already, the company is still expecting even more growth down the road.

In its earnings release, Curaleaf CEO Joseph Lusardi stated, “The recently announced acquisitions of Select and Grassroots, as well as, tuck in acquisitions in ArizonaCalifornia, Nevada, and Ohio position Curaleaf as the undisputed leader in the cannabis industry. With the industry’s largest operational footprint, we have the scale to rapidly accelerate growth across the country.”

More states looking to legalize pot

Thus far, we’ve seen 11 states in the U.S. legalize marijuana for recreational use. However, we could see that number grow, as both New York and New Jersey are two states that have shown interest in legalization, and other states are trying to get marijuana legalization on the ballot for 2020.

With more markets potentially becoming available, the growth potential for Curaleaf could get bigger very soon. For Canopy Growth, its path is not quite as clear.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »